Dermatologic Adverse Events Following CD19-Directed CAR T-Cell Therapy in Hematologic Malignancies. - Storgard R; Reingold RE; Parisi R; Dusza SW; Noor SJ; Park JH; Sauter CS; Curran KJ; Palomba ML; Shah G; Shouval R; Perales MA; et al. (Clinical lymphoma, myeloma & leukemia, 2026)